Peptide Medicine NY — how discoveries change course

GHK began in a liver culture

The familiar copper-peptide story starts in an unfamiliar organ. As recounted in the review of GHK and skin regeneration, GHK was isolated from human plasma in 1973 after work showing that it prompted older liver tissue to synthesize proteins more like younger tissue. This was tissue in a laboratory experiment. Nobody had demonstrated rejuvenation of a person.

The older experiment gives the familiar skincare association some history: a small signal from blood became interesting for tissue repair, and the copper-bound form acquired a long cosmetic life. The move from one setting to another is the interesting business here. It took further experiments, formulations and human topical studies to make a skincare case; the original observation could never supply all of that by itself.

New York offers a useful image for this: an old building put to a different use. Some foundations survive the conversion. Other things have to be rebuilt. Peptide medicine has its own versions of both.

A tanning relative, a desire medicine

Bremelanotide, also called PT-141, developed from the melanotan-II family, first explored for tanning. Its eventual approved indication concerns acquired, generalized low sexual desire in premenopausal women. A change of purpose that large deserves more than a picturesque origin story.

The RECONNECT trials measured sexual desire and distress about low desire. I’m struck by bremelanotide’s specificity, even when community discussion turns it into a general sexual-performance compound. The dedicated PT-141 article also includes a hamster experiment with a negative result on sexual reward.

Reusing a signal, designing a molecule

Semaglutide took a gut-hormone signal into diabetes treatment and then into other clinical uses. The SELECT trial tested cardiovascular events in people without diabetes, a particularly consequential change of question. I admire that willingness to ask a new question and then do the large trial it requires. Semaglutide peptide therapy has several distinct sets of results, each attached to its own population.

Retatrutide approaches reuse through molecular design. It combines activity at GIP, GLP-1 and glucagon receptors in a single engineered peptide. The Phase 2 obesity trial is substantial early clinical evidence; retatrutide remains investigational and unapproved. Calling a familiar body signal into a new arrangement creates fresh safety questions along with fresh possibilities.

Proposed combinations

Then there are the conversions suggested by a search box: GHK-Cu with retatrutide, a skin peptide alongside a metabolic one. The topical GHK review and the retatrutide obesity trial describe separate bodies of work. They supply no clinical test of the pair.

I enjoy a surprising connection. A combination claim still has to earn its own evidence. The GHK-Cu and retatrutide FAQ deals with that particular gap; the comparison lays out the different starting materials, uses and safety questions. For the oldest story here, continue with GHK-Cu.